Division of Molecular Biology and Human Genetics, Dept of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
Eur Respir J. 2014 May;43(5):1472-86. doi: 10.1183/09031936.00151413. Epub 2013 Dec 5.
Latent infection with Mycobacterium tuberculosis (LTBI) is defined by the presence of M. tuberculosis-specific immunity in the absence of active tuberculosis. LTBI is detected using interferon-γ release assays (IGRAs) or the tuberculin-skin-test (TST). In clinical practice, IGRAs and the TSTs have failed to distinguish between active tuberculosis and LTBI and their predictive value to identify individuals at risk for the future development of tuberculosis is limited. There is an urgent need to identify biomarkers that improve the clinical performance of current immunodiagnostic methods for tuberculosis prevention, diagnosis and treatment monitoring. Here, we review the landscape of potential alternative biomarkers useful for detection of infection with M. tuberculosis. We describe what individual markers add in terms of specificity for active/latent infection, prediction of progression to active tuberculosis and immunodiagnostic potential in high-risk groups' such as HIV-infected individuals and children.
潜伏性结核分枝杆菌感染(LTBI)定义为存在结核分枝杆菌特异性免疫而无活动性结核病。LTBI 的检测方法包括干扰素-γ释放试验(IGRAs)或结核菌素皮肤试验(TST)。在临床实践中,IGRAs 和 TST 未能区分活动性结核病和 LTBI,其预测个体未来发生结核病的风险的价值有限。迫切需要确定生物标志物,以提高当前用于结核病预防、诊断和治疗监测的免疫诊断方法的临床性能。在这里,我们回顾了用于检测结核分枝杆菌感染的潜在替代生物标志物的概况。我们描述了单个标志物在针对活动性/潜伏性感染的特异性、预测向活动性结核病的进展以及在高危人群(如 HIV 感染者和儿童)中的免疫诊断潜力方面的作用。